Scribd Logo
Upload

Welcome to Scribd!

  • 19 views

    New COVID-19 Impact On Biopharmaceutical Industry & CRO Outsourcing Report

    Uploaded by

    PR.com
    Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing

    Copyright:

    © All Rights Reserved

    New COVID-19 Impact On Biopharmaceutical Industry & CRO Outsourcing Report

    Uploaded by

    PR.com
    19 views2 pages
    Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing

    Original Title

    New COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report

    Copyright

    © © All Rights Reserved

    Did you find this document useful?

    Is this content inappropriate?

    Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing

    Copyright:

    © All Rights Reserved
    19 views2 pages

    New COVID-19 Impact On Biopharmaceutical Industry & CRO Outsourcing Report

    Uploaded by

    PR.com
    Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing

    Copyright:

    © All Rights Reserved
    of 2

    New COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing

    Report

    Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO
    Outsourcing

    Menlo Park, CA, April 30, 2020 --(PR.com)-- Life Science Strategy Group (LSSG), the leading strategic
    consulting firm to the CRO industry, is pleased to announce the launch of its new syndicated report,
    "COVID-19 Impact on the Biopharmaceutical Industry and CRO Outsourcing - 2020." This landmark
    study of 120 biopharmaceutical industry clinical development outsourcing decision makers in the US,
    Europe and China provides quantitative analysis, metrics, and insights into biopharmaceutical clinical
    development budgets, activity, outsourcing to CROs and future outlook in 2020. CROs highlighted by
    respondents in the report include Covance, ICON, IQVIA, PAREXEL, PPD, PRA Health Sciences and
    Syneos Health among others.

    The market research was conducted to better understand how and to what degree COVID-19 is impacting
    the biopharmaceutical industry, drug development activity and CRO outsourcing in the first half of 2020.
    The report also examines the outlook for the second half of 2020, what CROs are best positioned to
    capitalize on COVID-19 opportunities and which capabilities and services will biopharmaceutical
    sponsors increasingly need from CROs. According to Jon Meyer, Principal, Life Science Strategy Group,
    "Not surprisingly, we see that COVID-19 has dealt a significant blow to clinical development budgets,
    activity and outsourcing as patients shelter-in-place, as non-essential activities stop and
    biopharmaceutical sponsors rethink how to adapt the drug development paradigm to the new reality. The
    good news is that the biopharmaceutical industry has a positive outlook on the second half of 2020 and
    the quantitative results reflect that. Companies are 'rethinking' the traditional clinical trial, retooling and
    implementing innovative designs, remote patient-level technologies and leveraging the growing body of
    available, real-world data to overcome the challenges posed by COVID-19."

    To learn more about the impact of COVID-19 on the biopharmaceutical industry, CRO outsourcing and
    perceptions of CRO providers best prepared to support future biopharmaceutical clinical development
    needs, or to download sample pages from the report, visit https://lifesciencestrategy.com/publications.

    About Life Science Strategy Group, LLC


    Life Science Strategy Group, LLC is a consultancy specializing in strategic consulting, market research
    engagements and syndicated publications across a variety of therapeutic, technology and service
    industries including contract research services, pharmaceutical, biotechnology, medical devices,
    diagnostics and drug discovery.

    Page 1/2
    PR.com Press Release Distribution Terms of Use
    Contact Information:
    Life Science Strategy Group, LLC
    Jon Meyer
    1-800-941-6373
    Contact via Email
    www.lifesciencestrategy.com

    Online Version of Press Release:


    You can read the online version of this press release at: https://www.pr.com/press-release/811506

    Page 2/2
    PR.com Press Release Distribution Terms of Use

    You might also like